The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing.

Nieuwenhuizen, Natalie E; Kulkarni, Prasad S; Shaligram, Umesh; Cotton, Mark F; Rentsch, Cyrill A; Eisele, Bernd; Grode, Leander; Kaufmann, Stefan H E

Nieuwenhuizen, Natalie E; Kulkarni, Prasad S; Shaligram, Umesh; Cotton, Mark F; Rentsch, Cyrill A; Eisele, Bernd; Grode, Leander; Kaufmann, Stefan H E.

Afiliação

Nieuwenhuizen NE; Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany.
Kulkarni PS; Serum Institute of India Pvt. Ltd., Pune, India.
Shaligram U; Serum Institute of India Pvt. Ltd., Pune, India.
Cotton MF; Stellenbosch University, Tygerberg, South Africa.
Rentsch CA; Department of Urology, University Hospital Basel, Basel, Switzerland.
Eisele B; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.
Grode L; Vakzine Projekt Management GmbH, Hannover, Germany.
Kaufmann SHE; Vakzine Projekt Management GmbH, Hannover, Germany.

Front Immunol ; 8: 1147, 2017.

Article em En | MEDLINE | ID: mdl-28974949

Palavras-chave

VPM1002; bacille CalmetteGuérin; immune response; listeriolysin; tuberculosis; vaccine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Front Immunol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google